Abstract:OBJECTIVE: To explore changes in the plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in patients with left-to-right shunt congenital heart disease (CHD) before and in the early stage after interventional occlusion and to evaluate the clinical significance. METHODS: Among 97 patients with left-to-right shunt CHD undergoing interventional occlusion, 34 cases had a VSD (ventricular septal defect), 35 cases had an ASD (atrial septal defect), and 28 cases had PDA (patent ductus arteriosus). Another 20 normal adults formed the control group. An ELISA was used to determine the plasma ANP and BNP levels before and on the third day after the operation to evaluate their correlations with cardiac functions and the defect size. RESULTS: The plasma ANP and BNP levels of patients with left-to-right shunt CHD were increased compared with those of the normal control group (P < 0.01), and the plasma ANP and BNP levels were decreased on the third day after interventional occlusion compared with the preoperative levels (P < 0.05). The plasma ANP and BNP levels were correlated with the New York Heart Association (NYHA) grade, left ventricular ejection fraction and defect diameter (P < 0.05). CONCLUSION: Patients with left-to-right congenital heart disease exhibit activation of ANP and BNP, which can be alleviated in the early stage after intervention occlusion. Left-to-right shunt congenital heart disease is given priority over atrial septal defect (ASD), ventricular septal defect (VSD) and patent ductus arteriosus (PDA). Early traditional methods included repair or correction by open heart surgery under extracorporeal circulation (also known as cardiopulmonary bypass, CPB). However, interventional therapy has become a developing trend for the treatment of congenital heart disease since 1967, when Porstmann et al. [1]. reported the transcatheter closure of ASD for the first time. The application of the AMPLATZER occluder, which is a simple and feasible method, has improved the safety of the treatment and enabled the therapeutic effect to reach ideal levels. The natriuretic peptide (NP) family consists of the atrial natriuretic polypeptide (ANP), the brain natriuretic peptide, which is also known as the B type natriuretic peptide (BNP), the C type natriuretic peptide (CNP), the renal natriuretic peptide (RNP) and the D type natriuretic peptide (DNP). These family members are similar in structure, have strong natriuretic, diuretic and vasodilative effects and antagonize the activity of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nerve. Together, the natriuretic peptides sensitively and specifically reflect the ventricular function state. Although all types of congenital heart disease differ in anatomical structure, they all contain the common features of heart failure. This study detected changes in the serum ANP and BNP levels in patients with left-to-right shunt congenital heart disease before and on the third day after interventional occlusion to evaluate the early changes in left-to-right shunt congenital heart disease after interventional occlusion through neuroendocrine.

Pre and Post Intervention Neurohormonal Variation in Adults with Congenital Heart Diseases

Changes of Neurohormonal Level in Children with Congenital Heart Diseases at Pre-and Post-Interventional Therapy

Changes of Neuroendocrine Factor and Cardiac Index after Interventional Therapy

Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease

Study of Angiotensinii Level Fluctuation in Patients with Congenital Heart Diseases Pre- and Post-Interventional Therapy

Comparative Observation of Changes in Natriuretic Peptides Before and after Interventional Therapy for Congenital Heart Disease

The changes of the cardiotrophin 1 and brain natriuretic peptide in patients with angina and idiopathic dilated cardiomyopathy

Effects of pulmonary artery pressure on neurosecretory hormone in patients with congenital heart disease

N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease

Change and Clinical Significance of Angiotensin II and Endothelin-1 in Patients with Congestive Heart Failure

The Effect of Brain Natriuretic Peptide on Serum Angiotensin-Converting Enzyme 2 Levels in Acute Heart Failure Patients with Reduced Ejection Fraction

Exercise Training in Adults with Congenital Heart Disease

Level Change of Plasma N-terminal Pro-Brain Natriuretic Peptide Before and after Interventional Therapy and the Relationship with Cardiac Performance in Children with Ventricular Septal Defect

Changes of Plasma Adrenomedullin and Proadrenomedullin N-terminal 20 Peptide Concentrations in Patients with Heart Failure.

Changes of Adrenomedullin and Natriuretic Peptides in Patients with Adrenal Medullary Hyperplasia Prior to and Following Pharmacological Therapy and Adrenalectomy

Effects of Recombinant Human Brain Natriuretic Peptide on Aldosterone and Endothelin-1 in Treatment of Heart Failure

The changes of plasma levels of brain natriuretic peptides in evaluation of treatment responses in chronic heart failure]

Correlation Between Atrial Natriuretic Peptide and Renin-Angiotensin-aldosterone System in Congestive Heart Failure

Changes of blood N-terminal fragment of brain natriuretic peptide prohormone in patients with chronic heart failure

Determinants of N-terminal ProBNP Levels in Patients with Atrial Fibrillation and Preserved Left Ventricular Systolic Function